Regulation of Plant-Based Pharmaceuticals
Publication Date: March 2005
Publisher(s): Library of Congress. Congressional Research Service
Series: RS21418
Abstract:
Among many genetically engineered crops being developed are a number modified to produce pharmaceutical compounds (none yet commercialized). Proponents say such plant-based proteins could be produced more cheaply than by conventional methods and economically benefit farmers. But critics see risks, such as potential environmental, food safety, and trade problems. Among the issues is whether the current system for regulating biotechnology is adequate. This report will be updated if events warrant.
Sign up to receive email newsletters about the
latest research for the topic areas that
interest you.